"Another targeted agent for non-small-cell lung cancer (NSCLC) that is positive for the ALK rearrangement (found in about 5% of NSCLC patients) has just been approved by the US Food and Drug Administration (FDA). The new drug, alectinib ("...
There have been no known cases of XALKORI overdose. There is no antidote for XALKORI.
NoneThis monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 10/3/2015
Additional Xalkori Information
Report Problems to the Food and Drug Administration
Get the latest treatment options.